Christiane Eder

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Impact of assay procedures on detection of MR4.5 status in chronic myeloid leukemia: Optimization of cDNA synthesis.

Impact of assay procedures on detection of MR4.5 status in chronic myeloid leukemia: Optimization of cDNA synthesis.

Journal: International journal of laboratory hematology

Published: November 07, 2018

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.

Journal: Haematologica

Published: October 17, 2015

Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML.

Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML.

Journal: Annals of hematology

Published: June 18, 2015

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

Journal: Haematologica

Published: December 21, 2014

AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.

AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.

Journal: Leukemia research

Published: July 08, 2014

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Journal: Leukemia

Published: June 11, 2014

Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases.

Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases.

Journal: Haematologica

Published: February 06, 2014

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.

Journal: Blood cancer journal

Published: November 22, 2013

High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.

High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.

Journal: Leukemia

Published: November 20, 2013

The role of different genetic subtypes of CEBPA mutated AML.

The role of different genetic subtypes of CEBPA mutated AML.

Journal: Leukemia

Published: August 15, 2013

Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics.

Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics.

Journal: Leukemia

Published: May 08, 2013

High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia.

High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia.

Journal: Leukemia

Published: March 29, 2013

Showing 1-12 of 21

Last Updated: 09/26/2026